Company intelligence / Profile preview

Tempest Technology

Brisbane, California, United Statestempest.us.com ↗

Ownership: Private
Employees: ~5
Development stage: Other

Overview

Tempest Therapeutics is advancing small molecule therapeutics for oncology. Its lead asset, amezalpat, demonstrated a median survival benefit in HCC patients when combined with Tecentriq and Avastin versus standard-of-care alone. The company has received FDA fast track and orphan drug designations for amezalpat in HCC and is authorized to initiate a Phase 3 trial but lacks sufficient funding. Another candidate, TPST‑1495, targets familial adenomatous polyposis and is ready for Phase 2 trials.

Therapeutic areas: GastroenterologyOncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Currently none disclosed; actively seeking strategic partners or acquirers as of mid‑2025

Beyond the preview

Go deeper on Tempest Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tempest Technology.

Explore the full profile